

15 August 2024 (Thursday)  
The Pacific Sutera Hotel,  
Kota Kinabalu, Sabah  
Function Room 8, Level 3

Hepatology Update: Series 2/2024

# SHARP AND FOCUSED

## Updates on MAFLD

### Program

6.30 - 7.00pm

#### Registration

))) Expect an interactive session with iLivTouch FT100!

7.00 - 7.05pm

#### Welcome Speech by Datuk Dr. Raman Muthukaruppan Chettiar

7.05 - 7.25pm

#### Optimizing Use of Non-Invasive Tests in MAFLD

by Assoc. Prof. Dr. Terry Yip

7.25 - 7.45pm

#### Current & Emerging Therapy for MASH

by Prof. Dr. Chan Wah Kheong

7.45 - 8.05pm

#### Special Considerations in Managing MASH Patients with Cirrhosis

by Assoc. Prof. Dr. Terry Yip

8.05 - 8.30pm

#### Case Discussion

Panelists:  
Assoc. Prof. Dr. Terry Yip  
Dr. Tan Soek Siam  
Prof. Dr. Chan Wah Kheong

8.30pm

#### Closing Remarks & Adjourn for Dinner

))) Expect an interactive session with iLivTouch FT100!

Please RSVP by 12 August 2024

Contact Information: Tham Oi Yee +60 12 956 3992  
Thong Wen Dee +60 12 537 3992

Organized and endorsed by:



Sponsored by:



# The Speakers



## Assoc. Prof. Dr. Terry Yip

Terry graduated from The Chinese University of Hong Kong in 2014 with First Class Honor in B.Sc. in Statistics. He obtained his M.Phil. in Risk Management Science from The Chinese University of Hong Kong in 2016. During his M.Phil. study, he decided to devote himself to clinical research by applying his statistical knowledge. In 2019, he obtained his Ph.D. in Medical Sciences from The Chinese University of Hong Kong. In 2022, he finished 8 courses on Data Science in the Harvard Extension School.

Terry Yip is an Associate Professor in the Department of Medicine and Therapeutics at The Chinese University of Hong Kong. Terry's main research interest is big data approaches on patients with chronic liver diseases. His research includes different subpopulations of chronic hepatitis B including patients with resolved chronic hepatitis B, and patients who received different antiviral treatments. He also works on developing machine learning prediction models in patients with non-alcoholic fatty liver disease and diabetes mellitus. He has over 180 publications in peer-reviewed journals including *Lancet Gastroenterology & Hepatology*, *Gastroenterology*, *Journal of Hepatology*, *Gut*, and *Hepatology*.

He was awarded the Early Career Investigator Award in Clinical/Translational Science at AASLD meeting 2020, as well as the Young Investigator Award at APASL meeting 2018, 2022, and 2023, and in IDDF 2021 and 2022. He is now an Associate Editor of the *Journal of Hepatology*, *Frontiers in Gastroenterology - Hepatology*, and *Frontiers in Medicine - Hepatobiliary diseases*; and an Editorial Board member of *Clinical Gastroenterology and Hepatology*, *Alimentary Pharmacology & Therapeutics*, *Hepatology Communications*, and *Hepatoma Research*.



## Prof. Dr. Chan Wah Kheong

Dr Chan is Professor of Medicine Director, Director of the Division of Gastroenterology and Hepatology, and Senior Consultant Gastroenterologist and Hepatologist at the University of Malaya, the University of Malaya Medical Centre and the University of Malaya Specialist Centre. He served as an Executive Committee Member for the Malaysian Society of Gastroenterology and Hepatology (MSGH) between 2015 and 2021. He was the Scientific Co-Chair and a core member of the Organizing Committee for the Asian Pacific Digestive Week (APDW) 2021. He completed two terms as Associate Editor for the *Journal of Gastroenterology and Hepatology* between 2018 and 2023, and is a current member of the Editorial Board for *Clinical Gastroenterology and Hepatology*, *Alimentary Pharmacology and Therapeutics*, and *Clinical and Molecular Hepatology*.

He has published numerous full papers in peer-reviewed journals and presented in both local and international conferences. His main area of research interest is metabolic dysfunction-associated steatotic liver disease. As part of his PhD dissertation, he described the two-step approach in non-invasive assessment of liver fibrosis in non-alcoholic fatty liver disease (NAFLD), which has now become the foundation for a simple assessment and referral pathway for the disease in national and international guidelines. He contributed to the section on NAFLD in the 6th Edition of the *Clinical Practice Guidelines on the Management of Type 2 Diabetes Mellitus for Malaysia* and was the lead author for the MSGH Consensus Statements on metabolic dysfunction-associated fatty liver disease (MAFLD). He is a member of the Global NASH Council, the Asian Pacific Association for the Study of Liver MAFLD Consortium, the Gut and Obesity in Asia Workgroup, and the CAP Prognosis Study Group. Besides being an expert in the diagnosis and treatment of gastrointestinal and liver diseases, he is passionate about diagnostic and therapeutic endoscopic procedures, including endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography. He is involved in the training of fellows in Gastroenterology and Hepatology, and Advanced Therapeutic Endoscopy, and teaches undergraduate and postgraduate medical students. He contributed to two chapters in the core undergraduate reference book for clinical examination, *Talley & O'Connor's Clinical Examination 9th edition, Southeast Asia Edition*. He is a member of the Department of Medicine Higher Education Committee and is a regular reviewer for postgraduate research and grant proposals.

Organized and endorsed by:



Malaysian Society of  
Gastroenterology & Hepatology

Sponsored by:

